NCT06827431
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
StatusCompleted
PhasePhase 3
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 99 words Show 8 more changesShow less
- Completed without a posted recruiting period
- Study completion date changed from estimate of Sep 30, 2026 to Aug 20, 2026
- Enrollment target: estimated 770 to confirmed 786
- Study sites: 0 to 2
- Primary completion date changed from estimate of Jun 30, 2026 to Jul 14, 2026
- Start date changed from estimate of Feb 14, 2025 to Feb 21, 2025
- Secondary endpoints: details revised at 12 of 13 entries
- Collaborators expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)
Timeframe: From baseline to Week 8
Secondary (11)
Change from baseline in Hamilton Depression Scale (HAMD-17) at the end of treatment (week 8)
Change from baseline in The Clinical Global Impression Scale (CGI-S) scores at the end of treatment (week 8) at the end of treatment (week 8)
Clinical Global Impression Scale of Improvement (CGI-I) score at the end of treatment (week 8)
The efficiency and remission of the MADRS score
The efficiency and remission of the HAMD-17 score
Show 6 moreShow less
CGI-I score
Change from baseline in HAMD-17 score
Change from baseline in MADRS score
Change from baseline in HAMA score
Change from baseline in CGI-S score
The percentage of subjects with a MARDS score reduction ≥ 25%
Arms and interventions
Ammoxetine group-cohort 1Experimental
The eligible subjects will receive Ammoxetine plus placebo.
Ammoxetine group-cohort 2Experimental
The eligible subjects will receive Ammoxetine plus placebo.
Placebo groupPlacebo comparator
The eligible subjects will receive placebo.
Sertraline groupActive comparator
The eligible subjects will receive Sertraline plus placebo.
Drugs: Ammoxetine, Placebo, Sertraline
Sites
2 sites in 1 country